• Altered cellular immunity in patients with advanced head and neck cancer includes impairments in lymphokine production, blastogenesis, in vitro cytotoxicity, and T-cell levels. Recent evidence for the potential importance of in vivo cytotoxicity mediated by the lymphokine interleukin 2 (IL-2) in patients with cancer prompted a study of the kinetics of IL-2 receptor expression on lymphocytes from patients with untreated advanced head and neck cancer and normal subjects and an evaluation of the in vitro effects of the T-cell immune-reconstituting peptide, thymosin α1. Concanavalin A—stimulated IL-2 receptor expression was maximal after 72 hours and was higher in normal subjects than in patients. This was due to lower levels of helper/inducer (CD4) cells
Wolf GT, Hudson J, Peterson KA, Poore JA, McClatchey KD. Interleukin 2 Receptor Expression in Patients With Head and Neck Squamous Carcinoma: Effects of Thymosin α1 In Vitro. Arch Otolaryngol Head Neck Surg. 1989;115(11):1345–1349. doi:10.1001/archotol.1989.01860350079019
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.